On being hospitalised after contracting the coronavirus ( COVID-19), United States President Donald Trump was given a number of remedial solutions including a new drug called Regeneron.

Regeneron is in fact the name of the company with REGN-COV2 being the actual drug being administered. Since released from the Walter Reed Hospital, Trump has been singing the praises of what has come to be known as Regeneron and has attributed its properties to his speedy recovery.

“We have medicines right now and I call them a cure. I went into the hospital and I took this medicine (Regeneron) and it was incredible. I could have walked out the following day,” President Trump exclaimed.

He later went on to add, “I want to get you what I got. And I’m going to make it free. It’s a cure.”

It must be stressed here that Regeneron is yet to be proven to be safe and effective and, for all intents and purposes, is still in the experimental phase as it is yet to undergo a battery of clinical trials.

What are the next steps forward?

In an issued statement the company declared, “We have submitted a request to the U.S. Food and Drug Administration for an Emergency Use Authorization (EVA) for our REGN-COV2 investigational antibody combination for COVID-19. Under our agreement with the U.S. government for the initial doses of REGN-COV2, if an EVA is granted the government has committed to making these doses available to the American people at no cost and would be responsible (the government) for their distribution. At this time there are doses available for approximately 50,000 patients and we expect to have doses available for 300,000 patients in total within the next few months.”

The share price of Regeneron continues to rise on news of its new COVID-19 drug and its share price is now over US$600.

The biotech company says “ its medicines are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases and rare diseases.”